57 results about "Ischemic hypoxia" patented technology

The current invention provides a new organ preservation solution, suitable for machine perfusion, for maintaining viability of organs, parts of organs and tissues. This solution has been designed to overcome a number of problems associated with hypothermic machine perfusion of donor organs, in particular organs obtained from non-heart-beating donors. The solution prevents or minimizes the adverse affects caused by ischemia, hypoxia, energy and nutrient depletion, acidification, hypothermia and reperfusion injury. The preservation solutions according to the current invention are superior to current state of the art preservation solutions, in particular for preservation and perfusion of organs obtained from non-heart-bearing donors, by supplying increased concentrations and an optimized balance of amino acids, vitamins, anti-oxidants, high molecular weight additives and enhanced buffering capacity. In addition, the preservation solution according to the invention combines optimal physical and chemical properties with the use of readily available, inexpensive and pharmaceutically tested and acceptable compounds, reducing the cost of manufacturing and facilitating medical certification of solutions according to the current invention.

The present invention is one kind of Chinese medicine composition for treating cerebral hemorrhage and is preparation process. The Chinese medicine composition consists of effective components from motherwort, giant knotweed, leech, gentian, and buffalo horn or rhinoceros horn; and may be prepared into medicine powder, tincture, capsule, tablet, micro pill and other forms. The Chinese medicine composition has the function of promoting blood circulation to disperse blood clots, and can alleviate hemorrhagic apoplexy cerebral edema, promote the absorption of hematoma and disease focus repair, improve the ischemic and anoxic state of nerve tissue around hematoma, protect damaged brain cell and promote restoring of the nerve function.

The invention discloses a pre-adaptation training method based on high-concentration oxygen and low-concentration oxygen combination. The method is characterized in that the training method is based on gas, with different oxygen concentrations, output by a pre-adaptation training system; and the gas is inhaled by a user at different duration and frequencies, so that protection substances in the body of the user are stimulated. The method provides a safe and effective training measure for a trainee, and can be used for improving the human body anoxia-resistant or hypoxia-resistant capability through high-concentration oxygen and low-concentration oxygen alternate pre-adaptation training as a measure different from conventional medicine. The resistance capability of myocardial cells on ischemia and anoxia can be improved; endogenetic protection substances generated through stimulation are trained, and can achieve the nerve protection effect; the occurrence of serious ischemic stroke is prevented; endogenetic protection substances can also achieve the protection effect on important organs such as kidneys, intestines and lungs.

The invention provides a method for managing experimental animal respiration, which utilizes a clinic anesthesia machine for the anesthetization of the animal experiment, performs tracheal cannula on an animal, adopts an animal temperate maintenance instrument to keep warm, and keeps the body temperature at the physical level (37 plus or minus 0.5 DEG C) all the time during the anesthesia process. The method is used for solving the animal respiration management problem during the traditional anesthesia process, the same inhalation anesthesia concentration and the stable body environment are also maintained during the whole anesthesia process. By the method, not only is the stress response of the experimental animal reduced, but also the vital sign stability of the experimental animal can be maintained during the inhalation anesthesia process of a long time (such as 4 hours), the mortality is low and the reviving can be stable, and the influences of trauma stress, hypoxia-ischemia, hypercapnia, acidosis and other interference factors on the experimental result can be eliminated. The method effectively controls the respiratory tract of the experimental animal, and also maintains the inhalation anesthesia of the volatile anesthetics with constant concentration, which is output to the animal.

The invention discloses an adult sertoli cell-pancreas islet compound and a preparation method for the same, which solve the problem of influence on pancreas islet transplantation effect due to the transplant dysfunction because the pancreas islet separated and purified presently generates hypoxic-ischemic and immunological rejection reactions after being transplanted and then loses the function. The preparation method comprises the following steps of: 1, separating and purifying adult pancreas islet by adopting a semi-automatic filling and continuous density gradient methods; 2, separating and purifying adult sertoli cells by adopting a two-step digestion method; and 3, constructing the pancreas islet-sertoli cell compound by adopting a specific co-culture method. The adult sertoli cell-pancreas islet compound and the preparation method for the same disclosed by the invention have the advantage that pancreas islet cells and sertoli cells are coupled into a compound, the compound is used as a transplant, and the sertoli cells are attached to the surface of the pancreas islet, so as to improve the nutritional status of the pancreas islet, inhibit rejection reaction, and increase the survival rate of the pancreas islet; the operation is simple and convenient; and the success rate is high.

This invention relates to synthetic craft, preparation and new medicine function of a new water-solubility ramification of tanshinone iia: tanshinone iia sulfonic acid kalium ( potassium tanshinone iia sulfonate, PTS). The invention concretely relates to the pharmic application of tanshinone iia sulfonic acid kalium in prevention and treatment of myocardial ischemia and anoxia, cerebral ischemia and anoxia, microcirculation ameliorating, memory enhancing and corelated disease(cerebralthrombosis, acute cerebral ischemia, coronary heart disease, angina pectoris, myocardial infarction0.

The invention discloses application of a whole hemp extract in preparation of drugs for preventing and treating cardiovascular and cerebrovascular diseases. The whole hemp extract is prepared by evenly mixing 0.3-99.7 parts of an industrial hemp and fructus cannabis extract and 0.3-99.7 parts of an industrial hemp and cannabis sativa L extract. Experiments prove that the whole hemp extract has the effects of improving the activity of SOD, GSH-PX and other anti-free-radical enzymes, scavenging free radicals and protecting cardio and cerebral blood vessels and tissues and preventing and controlling occurrence and development of the cardiovascular and cerebrovascular diseases. The whole hemp extract can be used for preparing the drugs for preventing and treating the cardiovascular and cerebrovascular diseases, such as cerebral ischemia, myocardial ischemia, neuronal damage caused by hypoxia-reoxygenation, cerebral infarction (stroke), cerebral thrombosis, cerebral hemorrhage, a coronary heart disease and myocardial infarction and has the good application prospect in treatment or prevention of the cardiovascular and cerebrovascular diseases.

The invention discloses an application of a morindae officinalis extract and morindae officinalis oligosaccharide pentasaccharide to preparation of a drug for treating myocardial ischemia and / or reperfusion injury and promoting therapeutic angiogenesis. The myocardial ischemia and reperfusion injury belong to secondary injury brought to an organism when the hemoperfusion of myocardium is stopped or poor, i.e., after the myocardium is subjected to ischemia, hypoxia injury, circulation reinstitution and blood supply recovery. The morindae officinalis extract and the morindae officinalis oligosaccharide pentasaccharide both play a role in protecting an in-vivo rat myocardial ischemia reperfusion injury model and an in-vitro purification cultured neonatal rat myocardial cell hypoxia / reoxygenation injury model, and can be used for remarkably reducing the myocardial infarction area and the incidence rate of reperfusion arrhythmias, effectively protecting the form of a myocardial cell and relieving the injury of hypoxia / reoxygenation to the myocardial cell. The therapeutic angiogenesis promotion means that the aims of recovering the blood supply of ischemic myocardium and improving the heart function are achieved through increasing the functional coronary artery branch or side branch under the irritation actions of some methods, including the therapeutic actions of some drugs.

The invention relates to a Vitexin injection or oral administration preparation for treating cardiovascular diseases and process for preparation, wherein each 1000ml of the Vitexin injection comprises Vitexin 0.1-100g, each 1000 dosage units of the oral administration preparation comprises Vitexin 0.1-100g, and medicinal supplementary materials comprises diluent, flow aid, auxiliary solvent, excipient and osmoregulation agent.

The invention relates to levodopa preparation and application thereof. The levodopa preparation comprises, by weight percentage, 70-90% of levodopa and 10-30% of benserazide. The levodopa preparation has the advantages that the levodopa preparation contains the levodopa and the benserazide of fixed content, is applicable to rehabilitation treatment of cerebral dysfunction after cerebral resuscitation, and provides medicine for treating cerebral dysfunction caused by hypoxia-ischemia brain damage after cardio-pulmonary resuscitation; the preparation can be used to prepare medicine for repairing cerebral ischemia-reperfusion injury, medicine for the rehabilitation treatment of cerebral dysfunction after cerebral resuscitation, medicine for treating hypoxia-ischemia brain damage and medicine for replenishing body dopamine; meanwhile, a new purpose of levodopa is provided.

The present invention provides an application of ITPP in preparing medicines for preventing and / or treating ischemia-hypoxic injury and lung injury, and relates to the technical field of biomedicine.In the provided examples, mice and rats are used as experimental materials and a mouse ischemia-hypoxic model and a rat lung injury model are established to explore preventive or therapeutic effects of the ITPP on the ischemia-hypoxia injury and lung injury. Tests prove that the ITPP can significantly prolong survival time of mice with ischemia and hypoxia induced by high-dose isoprenaline in a closed container; and the ITTP can significantly improve lung functions, lung coefficients, right lung wet and dry weight ratios, arterial oxygen content, serum inflammatory factors and lung tissue pathological changes of rats of the LPS-induced lung injury model, and has a significant improvement effect on lung injury tissues.

The invention discloses a traditional Chinese medicine composition for regulating intestinal flora, which is characterized by comprising the following components in parts by weight: 10-15 parts of silkworm excrement, 6-9 parts of human middle yellow, 4.5-9 parts of trogopterus dung and 3-6 parts of tamarind sand. The invention further provides an application of the traditional Chinese medicine composition in preparation of medicines for improving vascular cognitive disorder related diseases. The vascular cognitive disorder related diseases are any one of non-dementia vascular cognitive disorder, vascular cognitive disorder complicated with sleep disorder, adrenal leukodystrophy, acute ischemic hypoxic encephalopathy, intestinal flora translocation encephalopathy, acute ischemic stroke andacute retinal central artery occlusion. The traditional Chinese medicine composition is simple in formula and wide in source, can effectively improve vascular cognitive impairment, and has a certain intervention effect on various accompanying risk factors such as hypertension, hypercholesterolemia, diabetes, metabolic syndrome and atherosclerosis.

The invention relates to the field of medical auxiliary instruments, in particular to a cage for preparing a rat model of ischemic hypoxic encephalopathy. The cage for preparing the rat model of the ischemic hypoxic encephalopathy comprises a box body, a cover body, a first sliding block, a first driving mechanism, a second sliding block and a second driving mechanism; an opening is formed in theupper side of the box body, a first air inlet pipe and a second air inlet pipe are arranged on the box body, the first sliding block is arranged in the box body in a sliding manner; the first drivingmechanism is arranged in the box body and is connected with the first sliding block; the second sliding block is arranged on the first sliding block in a sliding manner, and an air blowing pipe communicated with the second air inlet pipe is arranged on the second sliding block; the second driving mechanism is arranged on the first sliding block and is connected with the second sliding block; the cover body is buckled at the upper side of the opening, and an image acquisition device and an exhaust pipe are arranged on the cover body; and a controller is also included and is in communication connection with the image acquisition device, the first driving mechanism and the second driving mechanism. Through the arrangement mode, the oxygen concentration in the box body can be uniform, and theconsistency of the rat model is good.

The invention provides a molecular marker for diagnosing working of nervonic acid supplemented for ischemic hypoxic encephalopathy in a plateau environment and application of the molecular marker. Specifically, the invention relates to the application of the molecular marker, namely phosphatidylethanolamine-ceramide (d16: 1(4E) / 24: 1(15Z)) in preparation of an agent for diagnosing the working of nervonic acid supplemented for hypoxic-ischemic encephalopathy in the plateau environment. By detecting the molecular marker, whether acer truncatum bunge nervonic acid oil or similar nervonic acid products are absorbed and converted by an organism or not can be judged, and guiding significance is provided for whether the acer truncatum bunge nervonic acid oil or similar products have effects or not when the acer truncatum bunge nervonic acid oil or similar products are taken.

The invention provides a biomarker for diagnosing the working of nervonic acid supplemented for ischemic hypoxic encephalopathy and application of the biomarker. The biomarker comprises ceramide phosphate (d18: 1 / 24: 1(15Z)), and the ceramide phosphate is combined with any one selected from sphingomyelin (d18: 1 / 15: 0), docosapentaenoic acid, hexanoyl carnitine, phosphatidylcholine (22: 6( / 20: 5) or 2-hydroxyhexadecanoylcarnitine to diagnose whether the nervonic acid supplemented for the ischemic-hypoxic encephalopathy takes effect or not. According to the biomarker for diagnosing the working of nervonic acid supplemented for ischemic hypoxic encephalopathy, by detecting the biomarker, whether nervonic acid is absorbed and transformed by a body suffering from the ischemic hypoxic encephalopathy or not can be judged, and guiding significance is provided for judging whether acer truncatum bunge nervonic acid oil or similar products have effects or not when the acer truncatum bunge nervonic acid oil or similar products are taken by patients with the ischemic hypoxic encephalopathy.

The invention discloses application of Chaidamu agaricus bitorquis phenolic acid in the preparation of drugs, health products or food for protecting acute hypoxia injury and chronic hypoxia injury. The study of the application of the Chaidamu agaricus bitorquis phenolic acid in the preparation of the drugs, health products or food for protecting against acute hypoxia injury and chronic hypoxia injury shows that the Chaidamu agaricus bitorquis phenolic acid has the effects of prolonging death time of hypoxic mice in atmospheric pressure hypoxia-resistant test, prolonging urvival time of poisoned mice in sodium nitrite poisoning test and prolonging wheezing time of acute hypoxic mice in acute cerebral ischemic hypoxia test; the content levels of LDH (lactate dehydrogenase) and NO (carbon monoxide) can be reduced under the hypoxia conditions, the content level of ATP (adenosine triphosphate) is increased, the resistant ability of the hypoxia injury of a body is enhanced, and the compensation ability of the tissue for the acute hypoxia injury is improved; and the tissue is protected from hypoxia, and the Chaidamu agaricus bitorquis phenolic acid can be used as the safe and reliable anti-hypoxia drugs, health products or food.

The invention provides a pharmaceutical composition for increasing hypoxia tolerance, which is composed of natural amino acids, natural extracts and alpha-lipoic acid. The natural amino acids in the composition comprise ornithine or salts thereof and citrulline or salts thereof. The natural extracts are one or more substances selected from a safflower extract, a gingko extract or a Chinese-date extract. The pharmaceutical composition disclosed by the invention is capable of obviously increasing acute cerebral ischemic hypoxia survival time and increasing the oxygen utilization rate of tissue cells and has the function of increasing hypoxia tolerance. The pharmaceutical composition disclosed by the invention is prepared into troches or granules, which are applied to being taken by students, brain workers, the old and weak and sub-healthy people caused by hypoxia.

The invention relates to an application of neural stem cells in mediator influenced expression of protein P25 and P35, and discloses an application of neural stem cells in the preparation of P24 and / or P35 protein expression regulating agents, and an application of neural stem cells in the preparation of drugs for treating hypoxic-ischemic encephalopathy or neurodegenerative diseases. The research results show that neural stem cells (NSC) can modulate the expression change of P25 and P35 protein. The NSC can increase the P35 protein expression, reduce the P25 protein expression, and inhibit the excessive activation of Cdk5, thus protects and treats the brain damage, and has a prominent effect on diseases such as hypoxic-ischemic encephalopathy. A novel method and drug are provided for the brain damage diseases (HIE, etc.) and neurodegenerative diseases.

The invention provides a medicine used for treating varicocele induced sterility. The medicine comprises the following active pharmaceutical ingredients: epimedium herb, Chinese ligusticum rhizome, barbary wolfberry fruit, Chinese dodder seed, malaytea scurfpea fruit, tamariskoid spikemoss herb, radix astragali, red paeony root, common anemarrhena rhizome, rhizoma dioscoreae, herb of incisory spleenwort, all-grass of inconspicuous bulbophyllum, Chinese taxillus twig, gordon euryale seed, fruit of largeflower gardenia, suberect spatholobus stem, root of entire micromelum, penis and testis of ox, partition in fruit of English walnut, root of trifoliate acanthopanax, herb of henbit deadnettle and morinda root. The medicine has the beneficial effects that being matched with operative treatment, the medicine can achieve the effects of further promoting blood circulation of testes, improving ischemic hypoxia and metabolism and excretion of toxic substances, promoting improvement of the function of spermatogenesis and the quality of semen and reinforcing the sperm viability.

The invention relates to applications of carbazole compound in preparation of drugs or health care food used for treating metabolic diseases and complications of metabolic diseases. The carbazole compound is 3, 6-dibromo-beta-fluorine-N-(3-methoxyphenyl)-9H-carbazole-9-propylanmine (P7C3-A20). It is confirmed through high fat high sugar diet induced hyperlipidemia, obesity, and fatty liver animalmodel experiments that P7C3-A20 is capable reducing blood fat, blood sugar, obesity, and fatty liver lesion obviously; it is confirmed by cardiac muscle cell ischemic anoxic model simulated ischemic myocardial injury that P7C3-A20 is capable of reducing myocardial cell injury caused by ischemia and anoxia. The advantages are that: 1, the carbazole compound is capable of reducing blood fat, blood sugar, obesity, and fatty liver lesion obviously, preventing and treating fatty liver, and avoiding ischemic myocardial injury; and 2, a novel drug research direction is provided for metabolic bone disease and complications of metabolic bone diseases, and the application prospect is promising.

The invention relates to application of polymerized hemoglobin in preparation of a medicine for treating cerebral arterial thrombosis, the medicine is a hemoglobin oxygen carrier and is also a colloidal solution, and the particle size of the polymerized hemoglobin is only one thousandth of that of red blood cells. Small-dose perfusion does not bring tissue damage and cell death caused by reperfusion to the brain, but can relieve blood shortage caused by artery occlusion; meanwhile, hemoglobin carries out oxygen loading-oxygen unloading from the lung to tissues and organs, and targeted blocking is carried out on the pathophysiological process caused by ischemia and hypoxia of the brain; therefore, the nerve cells of the ischemic penumbra are saved, the death number of the nerve cells is reduced, and the nerve protection effect is achieved. A neuroprotective agent can also be added into the medicine disclosed by the invention to prepare a compound medicine, the protection effect on ischemic penumbra nerve cells is more obvious, and the 'therapeutic window' of stroke after rt-PA intravenous thrombolysis for 6 hours can be prolonged.

The present invention discloses application of salvianolic acid A in the preparation of drugs for treating acute kidney injury and belongs to the technical field of uses of traditional Chinese medicine effective ingredients. It is proved via pharmacodynamic experiments that salvianolic acid A can effectively relieve renal tubular necrosis and renal tubular microvascular endothelial cell injury, improve expression of vascular endothelium growth factors, inhibit the decrease in microvascular density, improve ischemic anoxic extent and thereby relieve rat renal tissue injury due to acute renal injury. Therefore, the salvianolic acid A may be used to prepare drugs for treating acute renal injury, thereby developing new uses of the salvianolic acid A.

The invention relates to the technical field of dental pulp stem and fine treatment, in particular to a method for treating cerebral ischemia reperfusion injury by using a dental pulp stem cell exosome. The method comprises the steps: extraction of exosomes from dental pulp stem cells, extraction of third molars without dental caries and periodontal lesions from healthy volunteers at age of 18 to 30 years-disinfection of tooth surface with 75% alcohol-removal of dental pulp from dental drill-cutting into pieces of 1 mm3-flushing three times with PBS containing 2.5% antibiotic-placement of pulp tissue in 1.5 ml EP tube with digestion of 3 mg / ml type I collagenase-placement in dispase of 4 mg / mL for 30 minutes at 37 DEG C-cell resuspension- and culturing in a 5% CO2 incubator at 37 DEG C; brain tissue is an organ most sensitive to ischemia and hypoxia of the body, irreversible brain injury occurs after blood flow supply is interrupted for several minutes, animal experiments find that the exosome from the dental pulp stem cells can reduce the cerebral infarction area after cerebral ischemia-reperfusion injury of a mouse, and a key technology is provided for clinical application of the dental pulp stem cell exosome in treatment of cerebral ischemia-reperfusion injury.

The invention discloses application of a P2X7 antagonist in preparation of medicament for treating myocardial ischemia injuries and hypertension / sympathetic nervous system diseases. Myocardial ischemia causes sympathetic excitoreflex (elevation of blood pressure, acceleration of heart rate and respiration and the like), and then myocardial ischemia injuries are aggravated. Cardiac sympathetic nervous erethism can also cause the elevation of blood pressure and then cause hypertension. The invention discloses a P2X7 receptor antagonist oxATP which can be used for reducing sympathetic nervous reflex caused by myocardial ischemia injuries and avoiding the phenomenon that myocardial ischemia and hypoxia are further aggravated due to cardiac sympathetic erethism, so that the myocardial ischemia injuries are relieved or alleviated. The hypertension can be prevented and cured by inhibiting cervical sympathetic ganglion erethism transmission. Sympathetic nervous diseases can be prevented and cured by inhibiting sympathetic erethism and related pathological processes. The mechanism of action of the oxATP in preventing and treating myocardial ischemia injuries, hypertension and sympathetic nervous lesions is as follows: the sympathetic excitation transmission mediated by cervical sympathetic ganglion P2X7 accepter is blocked, and an effect of preventing and treating the myocardial ischemia injuries, hypertension and sympathetic nervous diseases is generated.

The invention provides a rectum tissue oxygen saturation monitor which comprises an electrode, a balloon and an in-vitro monitoring component, the electrode comprises a near infrared spectrum electrode, the electrode is attached to the inner wall of the balloon, and the near infrared spectrum electrode is connected with the in-vitro monitoring component through a cable. The monitor disclosed by the invention can be used for effectively early warning ischemia and hypoxia phenomena of local tissues and intervening oxygen supply and demand imbalance of the local tissues, so that complications such as endotoxemia related to postoperative intestinal obstruction and intestinal barrier damage caused by ischemia and hypoxia of intestinal tracts in a perioperative period are prevented; and the method has important clinical value for accelerating postoperative intestinal function recovery and rapid ingestion and drinking.

The invention provides an application of plasma exosome CircOGDH as a diagnostic biomarker of acute ischemic stroke, and particularly relates to an application of plasma exosome CircOGDH as a diagnostic biomarker in preparation of a detection reagent, a diagnostic kit or a diagnostic preparation of acute ischemic stroke. The circular RNA CircOGDH disclosed by the invention is highly expressed in ischemic and hypoxic neurons after the acute ischemic stroke is attacked, and is transferred to peripheral blood from brain tissues through exosomes, so that the expression of the exosomes CircOGDH in plasma is increased, and the circular RNA CircOGDH can be used as a diagnostic biomarker for detecting the acute ischemic stroke. In addition, the plasma exosome CircOGDH disclosed by the invention, as a biomarker for diagnosing the AIS, has relatively high sensitivity and specificity and has a clinical popularization value.

The invention discloses the application of Codonopsis oligosaccharides in the preparation of drugs for preventing or treating gastrointestinal injury caused by hypoxia, the hypoxia being plateau hypoxia and / or tissue ischemic hypoxia; Methods for the preparation of polysaccharides. The beneficial effects of the present invention are: the application of Codonopsis oligosaccharides provided by the present invention in the preparation of drugs for preventing or treating gastrointestinal damage caused by hypoxia, the prepared drugs have good effects, and the drugs themselves Safe and effective, without toxic and side effects; it has been verified by experiments that drugs containing Codonopsis oligosaccharides can improve spleen atrophy and lung enlargement caused by high-altitude hypoxia in rats, enhance their antioxidant levels, improve inflammation, and relieve intestinal mucosal damage. Reducing EPO expression, and protein expression detection further indicated that Codonopsis oligosaccharides can reduce the expression of HIF-1α in the duodenum of high-altitude hypoxic rats.

Methods for deterring microglia-mediated neurotoxicity in a human or non-human animal subjects comprising the step of inhibiting or blocking the intermediate-conductance calcium-activated potassium channel KCa3.1 in microglia, such as in subjects how suffer from neurodegenerative diseases (e.g., Alzeheimer's Disease) or ischemic / anoxic / hypoxic conditions. The inhibition or blocking of the KCa1.3 channels may be accomplished by administering a KCa3.1 inhibiting substance, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34).

The invention belongs to the field of biological small molecule active peptides, and relates to an antioxidant peptide derived from morel fruit body protein, specifically an antioxidant peptide derived from morel and its preparation method and application. The antioxidant peptide comprises the following sequence: Ala-Tyr-Asp-Gln-Ile-Asp-Ala-Ala-Pro-Glu-Glu-Lys. The antioxidant peptide consists of 12 amino acids with a relative molecular mass of 1348Da. The invention isolates the natural anti-oxidation polypeptide from the morel fruit body, verifies and explains the mechanism of the polypeptide for preventing and treating ischemic-hypoxic brain injury. The obtained active polypeptide is an excellent neuroprotective agent, has the function of slowing down the damage of the nervous system caused by oxidative stress, and can be used in the preparation of anti-ischemic-hypoxic brain injury medicines or health care products.